(Q41248107)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Michael Bo Stoltenberg

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Hanne Lindegaard

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Pierre Bouchelouche

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Grith P Eng

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Klaus Bendtzen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Marcin Szkudlarek

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Viktoria Fana

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Emina Omerovic

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Pil Højgaard

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Elmo K Jensen

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

11 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

784825

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 3.0 Unported

2 March 2020

copyright license

start time

11 February 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339793

Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339793

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339793

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339793

Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339793

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339793

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339793

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339793

Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339793

Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339793

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339793

Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339793

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

19 August 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339793

30 September 2018

https://api.crossref.org/works/10.1155%2F2015%2F784825

Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity

21 January 2018

1 reference

12 December 2020

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

1 reference

12 December 2020

The Disease Activity Score and the EULAR response criteria

1 reference

12 December 2020

Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner

1 reference

12 December 2020

Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria

1 reference

12 December 2020

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?

1 reference

12 December 2020

Differential effect of drug interference in immunogenicity assays

1 reference

12 December 2020

The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region

1 reference

12 December 2020

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis

1 reference

12 December 2020

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

1 reference

12 December 2020

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

1 reference

12 December 2020

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

1 reference

12 December 2020

Identifiers

DOI

10.1155/2015/784825

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

PubMed publication ID

25759761

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25759761%20AND%20SRC:MED&resulttype=core&format=json